CEO Arthur Collins

Medtronic Inc. (NYSE: MDT) Revenue: 4.297 billion, up 4 percent from a year earlierNet income: $991 million, a 28 percent increase from a year earlierEarnings per share: 94 cents, a 31 percent increase from a year earlierCash and cash equivalents at the end of the quarter: $1.2 billion “I am pleased with our improved revenue growth this quarter in a dynamic healthcare environment,” said Omar Ishrak, Medtronic chairman and chief executive...  

and devices for vertebral compression fractures and spinal stenosis. Its CardioVascular segment offers coronary and peripheral stents and related delivery systems, endovascular stent graft systems, distal embolic protection systems, perfusion systems ...  

May 25 (Bloomberg) -- Bloomberg's Shannon Pettypiece reports on a catheter made by Medtronic Inc. that is used in an experimental 20-minute procedure to treat hypertension by cauterizing nerves near the kidneys that control blood pressure. (Source: Bloomberg)  

Fridley-based Medtronic Inc. (NYSE: MDT) reports its fourth-quarter and year-end financial results Tuesday morning. Estimates: Analysts expect quarterly earnings of 98 cents per share (up 8.9 percent from prior-year period) on revenue of $4.23 billion (down 1.5 percent from the prior-year period). That would bring full-year revenue to $16.3 billion and earnings to $3.45 per share. Last quarter: Medtronic's profits improved last quarter, but...  

Sales increases have resulted in a 4 percent increase in fiscal fourth quarter revenue for Fridley, Minn.-based Medtronic Inc. The company reported revenue of nearly $4.3 billion in the fourth quarter and nearly $16.2 billion for fiscal year 2012, an increase of 4 percent over $15.5 billion in fiscal year 2011. “Our growth was broad-based across our businesses and geographies, including strong U.S. launches of the Resolute Integrity drug...  

MINNEAPOLIS--(BUSINESS WIRE)--According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, the Resolute® drug-eluting stent (DES) from Medtronic, Inc. (NYSE:MDT) yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow...  

Business leaders in Minnesota need to take a active role in opposing a proposed amendment banning same-sex marriage, says former Medtronic Inc. CEO Bill George. George, in an opinion piece in the Star Tribune, says that the amendment's passage would make it more difficult for Minnesota's global companies to recruit top-level talent — "not just gays, but anyone whose choice is to be part of an open society that rewards performance over social...  

The U.S. Department of Justice and the Office of the U.S. Attorney for the District of Massachusetts have reportedly closed their investigation of Medtronic Inc. and its Infuse Bone Graft product, failing to find any wrongdoing on the company’s part. The Department of Justice began the investigation in October 2008. Designed in and is distributed out of Memphis, Infuse is a genetically engineered bone protein that stimulates bone growth. It...  

Medtronic Inc. said Wednesday that federal prosecutors have closed their four-year investigation into the medical device company's marketing of its Infuse bone-growth product. The investigation by the U.S. Department of Justice (DOJ) and the U.S. Attorney's Office in Massachusetts started in October 2008, Medtronic spokeswoman Cindy Resman said. She said the prosecutors received notification that they have closed the civil and criminal...  

Medtronic Inc. is best known for its medical technology, but the company is increasingly turning to IT experts to help fuel its business. The Wall Street Journal's has a report on Michael Hedges, the Fridley-based company's chief information officer, who's been charged by CEO Omar Ishrak to help grow Medtronic's $16 billion in sales. Some early tactics include using software to sort through hospital reports on devices and keep up with FDA...  

Medtronic Inc. said Wednesday it is laying off 220 people from a Twin Cities facility that makes pacemakers and implantable cardiac defibrillators. The layoffs are occurring at Medtronic's Cardiac Rhythm Management facility in Mounds View. Medtronic spokesman Steve Cragle said the 220 people already had been notified that their positions had been eliminated. He said the move is part of the normal adjusting of staffing levels based on market...  

The CEO of Medtronic Inc. is pledging to better track its medical devices after they're implanted in patients so it can catch potential problems earlier. Omar Ishrak told Reuters Monday that med-tech companies shouldn't rely on reports by doctors or patients to spot possible product problems. "We need improvements in device surveillance," he said, adding that Medtronic would invest heavily in tracking patient health after they get a device...  

A California woman has been sentenced to nearly four years in prison for selling $2.1 million of non-existent merchandise to Medtronic Inc. Jennifer Rutherford, 40, of San Jose, Calif., was sentenced by a federal judge in Minneapolis to 45 months in prison on one count of wire fraud, the U.S. Attorney's Office said. Rutherford worked as a senior marketing manager for Kyphon Inc., a Sunnyvale, Calif., spinal products company that Fridley...  

St. Jude Medical Inc. and Medtronic Inc. are going at each other over research comparing heart leads from the two med-tech heavyweights. Little Canada-based St. Jude has called on Heart Rhythm Journal to retract research published by Dr. Robert Hauser of the Minneapolis Heart Institute Foundation, who argued that St. Jude's Riata defibrillator leads were prone to failure, Reuters reported. In The New York Times, it widened the attack, saying...  

Medtronic Inc. is about to break ground on a $14 million, 75,000-square-foot building in Jacksonville, Fla. The Jacksonville Business Journal reports that the expansion by Fridley-based Medtronic (NYSE: MDT) will create 175 new full-time jobs by the end of 2015. Medtronic, which has nearly 700 employees in Jacksonville, is expanding its surgical technologies division. The company got $2.5 million in city and state incentives for the...  

Medtronic Inc. will break ground on a $14 million expansion project in Jacksonville next week. The medical technologies company will build a new 75,000 square-foot building to expand its surgical technologies division headquarters in Jacksonville and expects to create 175 new full-time jobs by the end of 2015. The ground breaking event is scheduled from 3 p.m. to 4 p.m. April 9 at the Medtronic headquarters at 6743 N. Southpoint Drive...  

Medtronic Inc.'s fiscal-fourth-quarter earnings rose 28% as the medical-device maker reported fewer charges but continued to face challenges in key heart- and spinal-device markets. Chairman and Chief Executive Omar Ishrak pointed to new products and the ...  

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year ended April 27, 2012. The company reported worldwide fourth quarter revenue of $4.297 billion, compared to the $4.167 billion reported in the fourth quarter of fiscal year 2011, an increase of 4 percent on a constant currency basis after adjusting for a $42 million negative foreign currency impact or 3 percent as...  

Medtronic Inc. is laying off about 1,000 workers worldwide – 250 of which are in the Twin Cities. The largest division in the Fridley medical technology company has struggled with slumping sales, according to the Associated Press. The company ...  

Medtronic Inc.'s (NYSE:MDT) fiscal fourth-quarter earnings rose 28% as the medical-device maker reported fewer charges and broad revenue growth. Chairman and Chief Executive Omar Ishrak said the revenue growth was broad based across its ...  

FRIDLEY, Minn. (AP) - Medtronic Inc. says it will cut 1,000 jobs in a fiscal 2013 restructuring plan. A Medtronic spokeswoman says about 250 jobs will be cut from the Minneapolis area where the medical device maker is based, and most of those employees ...  

Medical device maker Medtronic, Inc. ( MDT) on Tuesday posted a sharp uptick in fourth quarter earnings, but its outlook was just in-line with Wall Street estimates. The Minneapolis-based company reported fiscal fourth quarter net income of $991 ...  

Sales increases have resulted in a 4 percent increase in fiscal fourth quarter revenue for Fridley, Minn.-based Medtronic Inc. The company reported revenue of nearly $4.3 billion in the fourth quarter and nearly $16.2 billion for fiscal year ...  

Medtronic Inc.'s (MDT) fiscal fourth-quarter earnings rose 28% as the medical-device maker reported fewer charges and broad revenue growth. Chairman and Chief Executive Omar Ishrak said the revenue growth was broad based across its businesses ...  

Medtronic Inc. (MDT) is scheduled to release earnings on May 22, 2012, and ahead of that announcement, the company is looking strong. Given the relative position of the company amongst its peers, there are viable alternatives for every level of risk ...  

(RTTNews.com) - Medtronic, Inc. (MDT) posted fourth-quarter net earnings of $991 million or $0.94 per share, higher than last year's $776 million or $0.72 per share. Adjusted earnings per share for the quarter rose to $0.99 from $0.90 a year ...  

FRIDLEY (dpa-AFX) - Medtronic Inc. (MDT) on Tuesday said its fourth-quarter profit climbed 28 percent helped by sales growth, mainly in emerging markets. The medical devices maker's qua...  

Faced with no growth in two of its key medical-device markets, Fridley-based Medtronic said it would eliminate about 1,000 jobs, including 250 positions in the Twin Cities. Most of the local job cuts -- which were first disclosed by the company earlier this month -- are in Medtronic's heart rhythm device unit, which is based in Mounds View and makes pacemakers and implantable cardiac defibrillators. But Medtronic officials also said on Tuesday...  

MINNEAPOLIS--(BUSINESS WIRE)--In a continued commitment to help reduce the global burden of noncommunicable diseases (NCDs) such as cardiovascular disease and diabetes, the Medtronic Foundation is making a $435,000 grant to Partners in Health (PIH) to work with the Rwandan Ministry of Health to establish a team of NCD experts that will assist low-income countries in preparing National NCD Plans by 2013, a goal set by the United Nations...  

Medtronic Inc. ended its 2012 fiscal year with a strong fourth quarter, driven by continued emerging market growth and strong U.S. sales of the compan...  

PARIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from the Medtronic CoreValve® System. The study, presented at EuroPCR 2012, evaluated patients who were at high-risk for surgical aortic valve replacement. The Medtronic CoreValve System is currently limited to investigational use in the United States. The gender...  

PARIS--(BUSINESS WIRE)--Physicians presented today at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the BELLO and PACIFIER studies, each one showing statistically significant advantages of using an IN.PACT drug-eluting balloon from Medtronic, Inc. (NYSE: MDT) over a corresponding conventional treatment for coronary and peripheral artery disease. Medtronic IN.PACT drug-eluting balloons received CE (Conformité Europ...  

May 22 (Reuters) - Medtronic Inc reported higher quarterly earnings on Tuesday as weaker sales in its key markets for implantable heart defibrillators and spinal products were offset by stronger sales in its other divisions. Looking ahead to ...  

NEW YORK (MarketWatch) -- Medtronic Inc. said on Tuesday that its fiscal fourth-quarter profit roses to $991 million, or 95 cents per share, from $776 million, or 73 cents a share a year ago. The firm's net sales grew during the quarter to $4.30 billion, from $4.17 billion a year ago. The company's adjusted fourth-quarter profit totaled 99 cents a share. Analysts polled by FactSet Research had expected the company to earn 98 cents a share...  

PARIS--(BUSINESS WIRE)--As EuroPCR 2012 gets under way today, Medtronic, Inc. (NYSE: MDT) announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications, making it the drug-eluting stent (DES) with the broadest range of approved indications in Europe. The Resolute Integrity DES is now explicitly indicated in countries outside the United States that accept the CE mark for the...  

Medtronic Inc. (MDT), the world’s biggest maker of heart-rhythm devices, reported fourth-quarter profit that beat analyst estimates and said 2013 earnings will be as much as $3.70 a share. Profit excluding one-time items in the three months ...  

MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced results from the first and only clinical trial to show that Medtronic cardiac devices can safely extend detection time before triggering therapy in primary and secondary prevention patients. The ADVANCE III study, presented today as a late-breaking presentation at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions, evaluated patients...  

MINNEAPOLIS & BOSTON--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in Ambulatory Heart Failure Trial) trial demonstrating that cardiac resynchronization therapy with defibrillation (CRT-D) is a cost-effective treatment for mildly symptomatic heart failure patients. The findings showed a $33,025 (USD) cost per Quality Adjusted Life Year...  

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2012 on Tuesday, May 22, 2012. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic’s fourth quarter and fiscal year 2012, which ended April 27...  

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 27, 2012.  

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to approximately 1:00 p.m. Eastern Daylight Time. The meeting will include remarks from the Medtronic management team highlighting the company’s strategy for delivering improved growth and creating long-term shareholder value. Medtronic will host a webcast of the meeting to provide...  

Medtronic, Inc. (NYSE: MDT), a Minneapolis-based medical technology company, has announced the preliminary settlement of the securities class action pending against the company in the D. of Minnesota. The case, originally filed in 2008, stems from allegations that the company...  

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. is one of America’s best corporate citizens, according to the rankings recently released by Corporate Responsibility magazine. Medtronic made the top 50 list, moving up 16 spots from its 66th ranking in 2011. “Being a good corporate citizen is an important part of our Mission,” said Omar Ishrak, Medtronic chairman and chief executive officer. “We are proud of our accomplishments in Corporate...  

In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company's IN.PACT Admiral drug-eluting balloon.  

MINNEAPOLIS & LONDON--(BUSINESS WIRE)--Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity™ renal denervation system showing significant, sustained blood pressure reduction in patients with treatment-resistant hypertension. These data presented today at the European Society of Hypertension annual...  

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac resynchronization therapy with implantable cardioverter defibrillator (CRT-D) devices. With today’s approval, this advanced therapy can now be used earlier, in a mildly symptomatic heart failure patient population, potentially improving survival, reducing hospitalizations...  

NEW YORK (AP) -- Medical device maker Medtronic Inc. has agreed to pay $85 million to resolve a federal class action lawsuit brought by a group of shareholders. In December 2008, the Minneapolis Firefighters Relief Association filed a lawsuit alleging Medtronic made false and misleading public statements about its InFuse bone repair protein. The plaintiffs said Medtronic did not disclose how ...  

Medtronic paying $85M to end shareholder lawsuit NEW YORK (AP) — Medical device maker Medtronic Inc. has agreed to pay $85 million to resolve a federal class action lawsuit brought by a group of shareholders. In December 2008, the Minneapolis Firefighters Relief Association filed a lawsuit alleging Medtronic made false and misleading public statements about its InFuse bone repair protein. The ...  

Medtronic Inc. says it will shell out $85 million to settle a shareholder class action lawsuit stemming from its marketing of the controversial Infuse Bone Graft product. The lawsuit was filed in 2008 in Minneapolis federal court by institutional investors, … Continue reading →  

MINNEAPOLIS & LONDON--(BUSINESS WIRE)--In conjunction with the Charing Cross International Symposium (CX34), which concludes today in London, Minneapolis-based Medtronic, Inc. (NYSE: MDT) announced its plans for the imminent start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company’s IN.PACT Admiral™ drug-eluting balloon. The purpose of this...  

MEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the initiation of its launch of the POWEREASE™ System, an innovative system of electronic instruments designed specifically for use in instrumented, or reconstructive, spine surgery. This system brings new capability to the operating room through compatibility with two of the leading pedicle screw platforms on the market, the CD HORIZON® SOLERA™ Spinal System and the...  

FRIDLEY (dpa-AFX) - Medtronic Inc. (MDT) Sunday said that two separate study of Symplicity renal denervation system demonstrated safe and significant blood pressure reduction up to three years in patients with treatment-resistant hypertension. Renal denervation therapy is a minimally invasive, catheter-based procedure that...  

>via bizjournals.com Medtronic Inc. said Friday it will pay $85 million to settle a shareholders lawsuit that accused the company of making misleading statements about its controversial Infuse spinal product. Fridley-based Medtronic (NYSE: MDT) said in a news release that it "explicitly denies" that it engaged in any wrongdoing. The suit was filed in December 2008 by the Minneapolis Firefighters Relief Association, which claimed the company...  

MINNEAPOLIS (AP) - Medical device maker Medtronic Inc. said Wednesday that federal prosecutors have closed their investigation of the company's InFuse bone graft. The world's largest medical device company was being investigated by the U.S ...  

(Reuters) - Medtronic Inc said it agreed to pay $85 million to settle a shareholder lawsuit accusing it of making misleading statements concerning Infuse, a genetically engineered bone graft used in spinal surgery. The settlement resolves claims that Medtronic failed to reveal that as much as 85.2 percent of Infuse sales depended on so-called "off-label" uses, where doctors sometimes paid by ...  

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that the company has reached an agreement in principle to settle a previously disclosed federal securities class action. Under the settlement, the company will make a payment of $85 million to resolve all of the class claims. The action, initially filed in December, 2008 against the company and certain current and former officers by the Minneapolis Firefighters Relief...  

FRIDLEY (dpa-AFX) - Medtronic, Inc. (MDT) announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic CoreValve System in patients with severe aortic stenosis who are at high-risk for surgical aortic valve replacement, or SAVR. The data showed that patients in a real-world...  

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.ACC.12 Late-breaker Shows Promise of Pacemakers through Diminishing Fainting Recurrences in Patients Diagnosed with SyncopeMINNEAPOLIS & CHICAGO --(BUSINESS WIRE)-- 26.03.2012 --Medtronic, Inc. (NYSE: MDT) today...  

FRIDLEY (dpa-AFX) - Medtronic Inc. (MDT) announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting occurrences when treated with a Medtronic pacemaker. The company noted that the results found a statistically and...  

MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting occurrences when treated with a Medtronic pacemaker. The results, which found a statistically and clinically significant 57 percent relative reduction of fainting recurrence in patients at two years...  

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.MINNEAPOLIS --(BUSINESS WIRE)-- 24.03.2012 --Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic CoreValve® System in...  

Meanwhile, Medtronic profits grew for the third-consecutive quarter. Medtronic said Tuesday it is eliminating 1,000 jobs, which include 220 jobs in Mounds View that was reported early this month. But Medtronic spokeswoman Amy von Walter said the ...  

CHICAGO, March 27, 2012 /PRNewswire/ -- Zacks Equity Research highlights The Kroger Company (NYSE: KR) as the Bull of the Day and Dril-Quip, Inc. (NYSE: DRQ) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Medtronic (NYSE: MDT),Boston Scientific...  

Medtronic's earnings surged surged 28 percent higher in its fourth quarter over the same period last year on growth or stabilization across many of its businesses, the company said Tuesday. Minneapolis-based Medtronic posted profits of $991 ...  

Fridley-based Medtronic is eliminating about 1,000 jobs, including 250 positions in the Twin Cities. Medtronic officials disclosed the 1,000-job figure on Tuesday, May 22, as part of the medical-device company's release of fourth-quarter financial results.  

Medtronic, the world's largest medical device company, on Tuesday reported fourth quarter net earnings of $991 million, or $0.94 per diluted share -- an increase of 28 percent and 31 percent over the company's fourth quarter of 2011. The Fridley ...  

Chief Executive Omar Ishrak said he saw more stable market conditions ahead for Medtronic's key products, including implantable heart defibrillators and pacemakers, heart stents and products used in spinal surgery. While certain products in the ...  

WASHINGTON (Reuters) - Medtronic Inc plans to ramp up monitoring of its medical devices after they are implanted in order to catch potential safety problems earlier, as the industry wrestles with some headline-grabbing recalls.  

KAREMedtronic Receives Notification That U.S. Department of Justice and U.S. ...MarketWatch (press release)MINNEAPOLIS, May 16, 2012 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced it has been notified by the US Department of Justice (DOJ) and the Office of the United States Attorney for the District of Massachusetts that federal prosecutors ...Medtronic says bone graft investigation is overBoston.comDOJ closes investigation of...  

The Associated Press reported that Medtronic Inc. Wednesday, May 16, said federal prosecutors have closed their investigation of the company’s I...  

FRIDLEY, Minn.  — Medtronic Inc. is restructuring its cardiac rhythm disease management division and is laying off about 220 workers. The largest division in the Fridley medical technology company has  

Medtronic was off 1.5% to $37.15. Medtronic said its fourth-quarter income was $991 million, or 95 cents a share, up from the $776 million, or 73 cents a share, in the same period a year ago. Sales rose to $4.3 billion from $4.17 billion.  

Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT) is expanding availability of the Valiant ® Captivia ® Thoracic Stent Graft System in several countries, including China, Japan and the ...  

Medtronic Inc. will spend $50 million to expand research, training and manufacturing operations in Montreal after winning a $15 million grant from the Quebec government. The Montreal Gazette reports that the expansion will result in more than 200 new jobs ...  

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Medtronic%2C+Inc.+%28MDT%29+Resolves+Shareholder+Settlement+with+%2485+Million+Paymentx/7310998.html for the full story.  

A Medtronic Inc. device that attempts to lower high blood pressure showed promising results in a clinical trial after six months. The Fridley-based medical technology giant said it will present the ...  

A Medtronic Inc. device that attempts to lower high blood pressure showed promising results in a clinical trial after six months. The Fridley-based medical technology giant said it will present the data to doctors and researchers at the meeting ...  

While paying royalties to a doctor who envisions a new device is a legitimate expense ... Other busy legal areas for the company include employment law and mergers and acquisitions. Neither is a surprise for any high-tech company. Many of its new products ...  

The Montreal Gazette is reporting that Medtronic Inc. will receive $15 million from the Quebec government to help with a $50 million expansion of its research, training and manufacturing operations ...  

CHICAGO (Reuters) - Medtronic Inc said on Monday it agreed with research findings that favored the medical device maker's Sprint Quattro heart defibrillator lead over a rival product by St Jude Medical Inc.  

Medical device maker Medtronic Inc. said Wednesday that federal prosecutors have closed their investigation of the company's InFuse bone graft...  

Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. (NYSE: MDT - News) is expanding availability of the Valiant ® Captivia ® Thoracic Stent Graft System in several countries, including China ...  

Medical device maker Medtronic Inc. said Wednesday that federal prosecutors have closed their investigation of the company's InFuse bone graft.  

April 10 (Reuters) - Medtronic Inc said on Tuesday that the U.S. Food and Drug Administration had approved its implantable heart defibrillator with resynchronization therapy for a wider group of patients. The FDA approved the device, known as ...  

Medtronic Inc. is launching its new Powerease system, which uses electronic instruments to aid in spinal reconstructive surgery. Powerease is designed to work with spinal screws used in the CD Horizon Solera Spinal System, a spinal fusion system ...  

Medtronic, Inc., (NYSE: MDT), announced today six month pooled outcomes from randomized and crossover patients in the Symplicity HTN-2 clinical trial following renal denervation with the Symplicity™ renal denervation system showing significant, sustained ...  

Parker Waichman LLP, a national law firm dedicated to protecting the legal rights of people injured by defective drugs and medical devices, is currently evaluating potential lawsuit claims on behalf of individuals injured by off-label use of Medtronic Inc ...  

Medtronic, Inc. (NYSE:MDT), announced that the SymplicityTM renal denervation system provides safe, significant and sustained blood pressure reduction up to three years in patients with treatment-resistant hypertension, according to data from two clinical ...  

(RTTNews) - Medtronic Inc. (MDT: News ) announced, on April 15, the two-year results from its U.S. clinical study of the Endurant abdominal aortic aneurysms, or AAA Stent Graft System. The prospective Endurant U.S. investigational device exemption ...  

and ear, nose, throat surgery. About Medtronic Medtronic, Inc., headquartered in Minneapolis , is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.  

Wendy Morgan is participating in a US-based trial of Medtronic’s next generation Enlite Sensor for continuous glucose meters. This is currently only publicly available in Europe.  How do I love thee, Minimed Enlite trial continuous glucose sensor? Let me count the ways. Seriously folks, I love this sensor. I’ve had it on since Monday and I have had some hard diabetes days. I’ll get to that in another post, but so far, I can’t feel a thing and...  

Medtronic Inc. is backing findings of a study that raised serious safety concerns about Riata and Riata ST defibrillator leads made by rival, St. Jude Medical Inc. The study, conducted by Dr. Robert Hauser and published in the journal Heart ...  

Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc. (NYSE: MDT - News) announced today the start of the Medtronic IN.PACT SFA II study, the company ...  

Bolstering confidence in endovascular repair of abdominal aortic aneurysms (AAA), Medtronic Inc. (NYSE:MDT - News) announced yesterday the two-year results from its U.S. clinical study of the Endurant AAA Stent Graft System, the global market ...  

Medtronic, Inc. (NYSE: MDT) today announced that the company has reached an agreement in principle to settle a previously disclosed federal securities class action. Under the settlement, the company will make a payment of $85 million to resolve all of the ...  

Partners for this leg of the tour are Anthem Blue Cross, one of California’s top health insurance providers and Medtronic ... About Medtronic Medtronic, Inc., headquartered in Minneapolis, is the global leader in medical technology –– alleviating ...  

An emerging treatment for severe high blood pressure marketed by Medtronic Inc. (MDT) showed safety and effectiveness at one and three years in separate trials, the company said Sunday. The treatment, called renal denervation, is a cathether ...  

MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting ...  

Data from Two Clinical Trials Presented at the 61st Annual Scientific Session of the American College of Cardiology Show Consistent Effectiveness and Safety Up to Three Years MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT), announced ...  

According to new clinical data presented today at ACC.12 -- the 61 st Annual Scientific Session & Expo of the American College of Cardiology (ACC) -- the Resolute drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT) maintains a powerful and persistent ...  

But that is part of the strategy: earn cash returns of at least 8% per year (preferably 10-12%) until we get the stock at a discount to the current market price. In this article I will start by reviewing the results of what we have done thus far with this ...  

"In early 2011, Medtronic of Canada created a Diversity and Inclusion Coalition," said Andre Guerin, Director of Human Resources. "The Coalition's mandate is to promote a more inclusive culture by supporting the hiring and advancement of diverse groups and ...  

Novel devices from Medtronic Inc. (MDT) and Edwards Lifesciences Corp. (EW) that repair damaged aortic valves without open-heart surgery safely helped patients in two of the largest and longest reviews of the technology. A review of 399 patients ...  

Medtronic Inc. (MDT) said it agreed to pay $85 million to settle claims that executives misled shareholders about the profitability of the company’s Infuse bone-growth device. Medtronic, the world’s biggest maker of heart-rhythm devices ...  

Medtronic, Inc. (NYSE: MDT) today announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic CoreValve ® System in patients with severe aortic stenosis who are at high-risk for surgical aortic valve ...  

A Medtronic Inc. (MDT) device used to control hard-to-treat high blood pressure by burning overactive nerves with a burst of radio-frequency energy helped reduce the condition in 24 patients over three years in a study. The device, dubbed ...  

Rudolph F.X. Migliore, P.C. is investigating Medtronic cases to help victims of this dangerous medical device. New York (PRWEB) April 11, 2012 However, as numerous publications including the Wall Street Journal have reported, use of the Medtronic Infuse ...  

Some Medtronic insulin pumps are vulnerable to a hacking attack that could let someone break into the devices from 300 feet away, disable security alarms, acquire the serial number, and force them to dispense fatal insulin doses directly into diabetics’ bloodstreams, according to McAfee Inc. computer-security researcher Barnaby Jack. Research from a consortium of academics in 2008 found [...]  

It is also approved for use in two dental bone grafting procedures ... injuries causing severe and chronic pain Cancer According to a report from The New York Times, the analysis of Medtronic trial results Carragee presented in November showed ...  

It appears that St. Jude Medical Inc. has softened its criticism, somewhat, of Dr. Robert Hauser, the prominent cardiologist ... is helping his company,” Dr. Laurence M. Epstein, a heart device expert in Boston who consults for Medtronic ...  

Patients treated with a catheter-delivered heart valve marketed by Medtronic Inc. (MDT) had improvement in valve function but saw higher rates of mortality and stroke at six months than at one month, according to results from a large ...  

maintains a powerful and persistent treatment effect for a wide variety of patients with coronary artery disease, including those with diabetes mellitus, through two years of follow-up. “What's particularly striking about the two-year outcomes ...  

and raised serious concerns about the way Medtronic Infuse side effects were reported in clinical trials for the bone graft. Unfortunately, such scandals are nothing new for Infuse. Back in 2009, a Medtronic-paid surgeon at Walter Reed Army ...  

"Patients had great valve function after implantation with low stroke and mortality rates at three and six months," said Axel Linke, principal investigator and professor of medicine at Universitat Leipzig Herzzentrum in Germany. Dr. Linke is a ...  

FRIDLEY (dpa-AFX) - Medtronic, Inc. (MDT) announced results from its largest international, prospective, single-arm clinical trial evaluating the Medtronic CoreValve System in patients ...  

Company sees growth or stabilization across many of its businesses.  

FRIDLEY, Minn. (AP) – Medtronic Inc. is restructuring its cardiac rhythm disease management division and is laying off about 220 workers. The la...  

Medtronic Inc. is restructuring its cardiac rhythm disease management division and is laying off about 220 workers.  

Medical device maker Medtronic Inc. has agreed to pay $85 million to resolve a federal class action lawsuit brought by a group of shareholders.